Cleveland BioLabs Inc. (CBLI)’s Financial Results Comparing With BeiGene Ltd. (NASDAQ:BGNE)

This is therefore a comparing of the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation in Cleveland BioLabs Inc. (NASDAQ:CBLI) and BeiGene Ltd. (NASDAQ:BGNE). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cleveland BioLabs Inc. 1.77M 9.88 4.35M -0.39 0.00
BeiGene Ltd. 174.03M 46.33 507.77M -9.61 0.00

Table 1 highlights Cleveland BioLabs Inc. and BeiGene Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Cleveland BioLabs Inc. and BeiGene Ltd.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs Inc. -245.76% -734.3% -56.6%
BeiGene Ltd. -291.77% -38.8% -29.6%

Liquidity

The Current Ratio and Quick Ratio of Cleveland BioLabs Inc. are 3.5 and 3.5 respectively. Its competitor BeiGene Ltd.’s Current Ratio is 11.6 and its Quick Ratio is 11.5. BeiGene Ltd. can pay off short and long-term obligations better than Cleveland BioLabs Inc.

Institutional & Insider Ownership

Cleveland BioLabs Inc. and BeiGene Ltd. has shares owned by institutional investors as follows: 6% and 77.8%. 58.15% are Cleveland BioLabs Inc.’s share owned by insiders. Comparatively, insiders own roughly 0.1% of BeiGene Ltd.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cleveland BioLabs Inc. -4.28% 1.7% -1.65% -33.95% -28.69% -55.36%
BeiGene Ltd. -11.06% 10.42% -17.53% -31.81% 41.72% 39.54%

For the past year Cleveland BioLabs Inc. has -55.36% weaker performance while BeiGene Ltd. has 39.54% stronger performance.

Summary

On 6 of the 10 factors BeiGene Ltd. beats Cleveland BioLabs Inc.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to develop and commercialize BeiGene, Ltd.Â’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317. BeiGene, Ltd. was founded in 2010 and is based in Camana Bay, Cayman Islands.